OBX NASDAQ
Obsidian Therapeutics Inc.
1W: +5.7%
1M: -20.1%
YTD: -22.3%
$13.59
+0.27 (+2.03%)
Weekly Expected Move ±13.2%
$10
$12
$14
$15
$17
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$14.1M
52W Range12.16-49.97
Volume228,988
Avg Volume372,502
Beta2.60
Dividend—
Analyst Ratings
No analyst coverage
Company Info
CEOMadan Jagasia
Employees87
SectorHealthcare
IndustryBiotechnology
IPO Date2026-08-04
Websiteobsidiantx.com
1030 Massachusetts Avenue
Cambridge, MA 02138
US
Cambridge, MA 02138
US
About Obsidian Therapeutics Inc.
A clinical-stage biopharmaceutical company harnessing novel protein-regulation technology to develop engineered tumor-infiltrating lymphocyte (TIL) cell therapies for the treatment of patients with solid tumors. Its proprietary cytoDRiVE® technology is designed to precisely regulate the timing and level of protein function by using FDA-approved small-molecule drugs.
Latest News
No recent news
Recent Insider Trades
No insider trades found